Hansa Biopharma AB (publ) (HNSBF) Q1 2025 Earnings Call Transcript

2025-04-24 13:39:43 ET

Hansa Biopharma AB (publ) (HNSBF)

Q1 2025 Earnings Conference Call

April 24, 2025 08:00 AM ET

Company Participants

Peter Nicklin - Chairman of the Board

Hitto Kaufmann - Chief R&D Officer

Evan Ballantyne - Chief Financial Officer

Renée Lucander - Chief Executive Officer

Conference Call Participants

Suzanne van Voorthuizen - Kempen

Douglas Tsao - H.C. Wainwright

Eric Yeung - William Blair

Chris Uhde - SEB

Presentation

Operator

Good day and welcome to the Hansa Biopharma Interim Results and Q1 Earnings Conference Call. All participants will be in listen-only mode. [Operator Instructions] Please note this event is being recorded.

I would now like to turn the conference over to Peter Nicklin, Chairman of the Board Hansa Biopharma. Please go ahead.

Peter Nicklin

Good afternoon and good morning everybody. Welcome to the Hansa Biopharma conference call to review our Q1 results for 2025. I'm Peter Nicklin Chairman of the Board of Hansa Biopharma. You'll recollect in June this year, I actually reached my 30-year anniversary as Chairman of the Board.

Joining me today is Evan Ballantyne, Chief Financial Officer; Hitto Kaufmann, our Chief R&D Officer; and Renée Lucander our newly appointed CEO. Before we turn to the Q1 results you are most likely aware that earlier today we announced the departure of Søren Tulstrup, CEO of Hansa Biopharma effective immediately. Over the course of his tenure whilst with the organization Søren successfully navigated the company through several key milestones and financial rounds. The Board and I certainly appreciate his leadership and commitment to the company and wish him well for any future endeavors.

Later in the call we will hear from Renée who has been appointed as CEO effective immediately. Today is her first day at Hansa and while she is in the room with me here, I trust that you will agree that it would be unfair to ask her to host this call with you today....

Read the full article on Seeking Alpha

For further details see: